A Study of Tenecteplase for Restoration of Function in Dysfunctional Central Venous Catheters (TROPICS 1)

This study has been completed.
Sponsor:
Information provided by:
Genentech
ClinicalTrials.gov Identifier:
NCT00395876
First received: November 2, 2006
Last updated: July 14, 2010
Last verified: July 2010
  Purpose

This was a Phase III, randomized, double-blind, placebo-controlled study that was conducted at 24 centers in the United States and Canada. 100 adult and pediatric patients with dysfunctional central venous catheters (CVCs) were randomly assigned in a 1:1 ratio to receive an initial dose of either placebo (Arm A) or tenecteplase (Arm B).


Condition Intervention Phase
Dysfunctional Central Venous Access Catheters
Drug: placebo
Drug: tenecteplase
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Tenecteplase for Restoration of Function in Dysfunctional Central Venous Catheters

Resource links provided by NLM:


Further study details as provided by Genentech:

Primary Outcome Measures:
  • Percentage of Patients Who Had Restoration of Central Venous Catheter (CVC) Function Following a Single Administration of Study Drug [ Time Frame: 120 minutes after first dose ] [ Designated as safety issue: No ]
    Restoration of CVC function was defined as successful withdrawal of at least 3 mL of blood or fluid and infusion of 5 mL of normal saline in patients weighing ≥ 10 kg, and withdrawal of at least 1 mL of blood or fluid and infusion of 3 mL of normal saline in patients weighing < 10 kg.


Secondary Outcome Measures:
  • Percentage of Patients Who Had Restoration of CVC Function Following a Single Administration of Study Drug [ Time Frame: 15 minutes after first dose ] [ Designated as safety issue: No ]
    Restoration of CVC function was defined as successful withdrawal of at least 3 mL of blood or fluid and infusion of 5 mL of normal saline in patients weighing ≥ 10 kg, and withdrawal of at least 1 mL of blood or fluid and infusion of 3 mL of normal saline in patients weighing < 10 kg.

  • Percentage of Patients Who Had Restoration of CVC Function Following a Single Administration of Study Drug [ Time Frame: 30 minutes after first dose ] [ Designated as safety issue: No ]
    Restoration of CVC function was defined as successful withdrawal of at least 3 mL of blood or fluid and infusion of 5 mL of normal saline in patients weighing ≥ 10 kg, and withdrawal of at least 1 mL of blood or fluid and infusion of 3 mL of normal saline in patients weighing < 10 kg.

  • Percentage of Patients Who Had Restoration of CVC Function Following a Second Administration of Study Drug [ Time Frame: 15 minutes after second dose ] [ Designated as safety issue: No ]
    Restoration of CVC function was defined as successful withdrawal of at least 3 mL of blood or fluid and infusion of 5 mL of normal saline in patients weighing ≥ 10 kg, and withdrawal of at least 1 mL of blood or fluid and infusion of 3 mL of normal saline in patients weighing < 10 kg.

  • Percentage of Patients Who Had Restoration of CVC Function Following a Second Administration of Study Drug [ Time Frame: 30 minutes after second dose ] [ Designated as safety issue: No ]
    Restoration of CVC function was defined as successful withdrawal of at least 3 mL of blood or fluid and infusion of 5 mL of normal saline in patients weighing ≥ 10 kg, and withdrawal of at least 1 mL of blood or fluid and infusion of 3 mL of normal saline in patients weighing < 10 kg.

  • Percentage of Patients Who Had Restoration of CVC Function Following a Second Administration of Study Drug [ Time Frame: 120 minutes after second dose ] [ Designated as safety issue: No ]
    Restoration of CVC function was defined as successful withdrawal of at least 3 mL of blood or fluid and infusion of 5 mL of normal saline in patients weighing ≥ 10 kg, and withdrawal of at least 1 mL of blood or fluid and infusion of 3 mL of normal saline in patients weighing < 10 kg.

  • Percentage of Patients Who Had Restoration of CVC Function Following a Third Administration of Study Drug [ Time Frame: 15 minutes after third dose ] [ Designated as safety issue: No ]
    Restoration of CVC function was defined as successful withdrawal of at least 3 mL of blood or fluid and infusion of 5 mL of normal saline in patients weighing ≥ 10 kg, and withdrawal of at least 1 mL of blood or fluid and infusion of 3 mL of normal saline in patients weighing < 10 kg.

  • Percentage of Patients Who Had Restoration of CVC Function Following a Third Administration of Study Drug [ Time Frame: 30 minutes after third dose ] [ Designated as safety issue: No ]
    Restoration of CVC function was defined as successful withdrawal of at least 3 mL of blood or fluid and infusion of 5 mL of normal saline in patients weighing ≥ 10 kg, and withdrawal of at least 1 mL of blood or fluid and infusion of 3 mL of normal saline in patients weighing < 10 kg.

  • Percentage of Patients Who Had Restoration of CVC Function Following a Third Administration of Study Drug [ Time Frame: 120 minutes after third dose ] [ Designated as safety issue: No ]
    Restoration of CVC function was defined as successful withdrawal of at least 3 mL of blood or fluid and infusion of 5 mL of normal saline in patients weighing ≥ 10 kg, and withdrawal of at least 1 mL of blood or fluid and infusion of 3 mL of normal saline in patients weighing < 10 kg.

  • Percentage of Patients Who Had Restoration of CVC Function Following Administration of One or Two Doses of Tenecteplase [ Time Frame: Up to 120 minutes post-treatment ] [ Designated as safety issue: No ]
    Restoration of CVC function was defined as the successful withdrawal of at least 3 mL of blood or fluid and infusion of 5 mL of normal saline in patients weighing ≥ 10 kg, and withdrawal of at least 1 mL of blood or fluid and infusion of 3 mL of normal saline in patients weighing < 10 kg.

  • Percentage of Patients Who Had Restoration of CVC Function at Any Time During the Study and Who Maintained Catheter Patency the Next Time the Catheter Was Assessed, up to 7 Days Following the Last Dose of Tenecteplase [ Time Frame: Up to 7 days post-treatment ] [ Designated as safety issue: No ]
    Restoration of CVC function was defined as the successful withdrawal of at least 3 mL of blood or fluid and infusion of 5 mL of normal saline in patients weighing ≥ 10 kg, and withdrawal of at least 1 mL of blood or fluid and infusion of 3 mL of normal saline in patients weighing < 10 kg.


Enrollment: 100
Study Start Date: November 2006
Primary Completion Date: June 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo + Tenecteplase + Tenecteplase (PTT) Drug: placebo
2 mL of placebo instilled into lumen of dysfunctional CVC. Patients weighing ≥ 30 kg received 2-mL instillations of study drug (i.e., 2 mg of placebo). Patients weighing < 30 kg received instillations of study drug equal to 110% of the internal lumen volume of the dysfunctional CVC. This dose was rounded to the nearest 0.1 mL and should not have exceeded 2 mL (2 mg).
Drug: tenecteplase
2 mL of reconstituted lyophilized tenecteplase instilled into lumen of dysfunctional CVC. Patients weighing ≥ 30 kg received 2-mL instillations of study drug (i.e., 2 mg of tenecteplase). Patients weighing < 30 kg received instillations of study drug equal to 110% of the internal lumen volume of the dysfunctional CVC. This dose was rounded to the nearest 0.1 mL and should not have exceeded 2 mL (2 mg).
Experimental: Tenecteplase + Tenecteplase + Placebo (TTP) Drug: placebo
2 mL of placebo instilled into lumen of dysfunctional CVC. Patients weighing ≥ 30 kg received 2-mL instillations of study drug (i.e., 2 mg of placebo). Patients weighing < 30 kg received instillations of study drug equal to 110% of the internal lumen volume of the dysfunctional CVC. This dose was rounded to the nearest 0.1 mL and should not have exceeded 2 mL (2 mg).
Drug: tenecteplase
2 mL of reconstituted lyophilized tenecteplase instilled into lumen of dysfunctional CVC. Patients weighing ≥ 30 kg received 2-mL instillations of study drug (i.e., 2 mg of tenecteplase). Patients weighing < 30 kg received instillations of study drug equal to 110% of the internal lumen volume of the dysfunctional CVC. This dose was rounded to the nearest 0.1 mL and should not have exceeded 2 mL (2 mg).

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Clinically stable, in the opinion of the investigator
  • CVC occlusion
  • Able to have fluids infused at the volume necessary to instill study drug into the CVC

Exclusion Criteria:

  • Able to have 3 mL of blood (patients weighing ≥ 10 kg) or 1 mL of blood (patients weighing < 10 kg) withdrawn from the selected study CVC following patient repositioning
  • Selected study CVC inserted < 2 days prior to treatment
  • Selected study CVC known to be dysfunctional for > 7 days
  • Selected study CVC implanted specifically for hemodialysis (HD)
  • Use of a power injector on the selected study CVC during the study
  • Evidence of mechanical, non-thrombotic occlusion of the selected study CVC (e.g., kink in the catheter or suture constricting the catheter)
  • Previously treated in this study or any tenecteplase catheter clearance trial
  • Use of any investigational drug or therapy within 28 days prior to treatment
  • Use of a fibrinolytic agent (e.g., alteplase, tenecteplase, reteplase, or urokinase) within 24 hours prior to treatment
  • Known to be pregnant or breastfeeding at screening
  • CVC with known or suspected infection
  • History of any intracranial hemorrhage, aneurysm, or arteriovenous malformation
  • Use of heparin (unfractionated or low molecular weight) within 24 hours prior to treatment, except for use of intermittent or low-dose, continuous infusion of heparin to maintain catheter or vessel patency
  • Use of warfarin within 7 days prior to treatment, except for low-dose warfarin used for prophylaxis
  • Initiation of or increase in dose of Plavix® (clopidogrel bisulfate) within 7 days prior to treatment
  • At high risk for bleeding events or embolic complications (i.e., recent pulmonary embolus, deep vein thrombosis, endarterectomy, or clinically significant right-to-left shunt) in the opinion of the investigator, or with known condition for which bleeding constitutes a significant hazard
  • Known hypersensitivity to tenecteplase or any component of the formulation
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00395876

Sponsors and Collaborators
Genentech
Investigators
Study Director: Richard Levine, M.D.
  More Information

No publications provided by Genentech

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Clinical Trials Posting Group, Genentech, Inc.
ClinicalTrials.gov Identifier: NCT00395876     History of Changes
Other Study ID Numbers: N3698g
Study First Received: November 2, 2006
Results First Received: July 14, 2010
Last Updated: July 14, 2010
Health Authority: United States: Food and Drug Administration

Keywords provided by Genentech:
TNKase
CVA
CVAD
Central venous access catheter
CVA catheter

Additional relevant MeSH terms:
Tenecteplase
Tissue Plasminogen Activator
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Cardiovascular Agents
Therapeutic Uses
Hematologic Agents

ClinicalTrials.gov processed this record on September 16, 2014